Delivery Order V797D70252-36C26221F0127
Award Date
12/28/20
Potential Completion Date
2/28/21
Potential Value
$292K
Federal Agency
Veterans Integrated Service Network 22
Awardee
Gilead Sciences Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Carrollton, TX 75010, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Veterans Affairs (VA) Veterans Health Administration awarded a delivery order contract to Gilead Sciences Inc., a biopharmaceutical company, to provide 100mg vials of the COVID-19 treatment drug remdesivir (branded as Veklury). The $155,700.00 firm fixed-price contract has a completion date of November 30, 2020 and is issued under Gilead's GSA Schedule 61-IB Pharmaceuticals and Drugs contract. This is one of several contracts the VA has awarded Gilead to supply antiviral and...
This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Gilead Sciences Inc. for the supply of INV-REMDESIVIR 100MG (COVID-19) with a potential value of $175,162.50. The contract was awarded under Gilead's General Services Administration (GSA) Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs. Gilead will deliver the COVID-19 treatment medication directly to VA medical facilities. As a small business set-aside was...
This is a federal delivery order contract awarded by the Veterans Integrated Service Network (VISN) 16 of the U.S. Department of Veterans Affairs (VA) to Gilead Sciences Inc., a large biopharmaceutical company. The contract is for the supply of Veklury (remdesivir), a COVID-19 treatment medication. The contract has a ceiling value of $77,850.00 and was awarded on December 23, 2020, with a completion date of January 22, 2021. The contract was awarded under GSA Schedule 61-IB for Pharmaceuticals...
This federal contract award is a delivery order under Gilead Sciences Inc.'s General Services Administration (GSA) Schedule 61-IB contract for Pharmaceuticals and Drugs. The $81,742.50 firm fixed-price contract was awarded by the U.S. Department of Veterans Affairs (VA) for Veklury (remdesivir), an antiviral medication used to treat COVID-19. The contract has an ultimate completion date of September 30, 2021 and was not set aside for small businesses. Gilead Sciences, the prime contractor, is...
This is a delivery order under the GSA Schedule 61-IB for Pharmaceuticals and Drugs, awarded by the U.S. Department of Veterans Affairs (VA) to Gilead Sciences Inc. (Gilead) for the COVID-19 treatment Veklury (remdesivir). The $77,850 fixed-price contract has a performance period ending on March 31, 2021. Gilead, a large biopharmaceutical company, is the sole-source manufacturer of Veklury and a key supplier of critical medications to federal healthcare programs, particularly the VA. The...
This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Gilead Sciences Inc. (Gilead) for the emergency procurement of the antiviral drug remdesivir (Veklury). The contract has a potential value of $194,625.00 and a completion date of December 31, 2020. This order is placed against Gilead's existing Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). Gilead, a biopharmaceutical company, has...
This federal contract award, valued at $77,850.00, was made by the Department of Veterans Affairs (VA) to Gilead Sciences Inc. (Gilead) for the delivery of the COVID-19 treatment Remdesivir (100mg). The contract was awarded on December 16, 2020, with an ultimate completion date of December 23, 2020. The contract was issued as a delivery order under Gilead's existing General Services Administration (GSA) Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). As the...
This federal contract award is for the delivery of VEKLURY REMDESIVIR 437, an emergency pharmaceutical supply, to the Veterans Integrated Service Network 23 (VISN 23) of the U.S. Department of Veterans Affairs (VA). The $89,916.75 firm fixed-price delivery order was awarded to Gilead Sciences Inc., a large biopharmaceutical company, under the GSA Schedule 61-IB for Pharmaceuticals and Drugs. This contract does not have a set-aside designation. Gilead holds a $29.16 million Blanket Purchase...
This is a federal contract award to Gilead Sciences Inc., a biopharmaceutical company, for the provision of REMDESIVIR 100MG SOLID. The contract was awarded on December 4, 2020 by the Department of Veterans Affairs Veterans Health Administration, with a potential value of $233,550.00. The contract is a Delivery Order under Gilead's General Services Administration (GSA) Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB), indicating that Gilead is an established supplier of...
This federal contract award, with a ceiling value of $10,205.10, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Veklury (Remdesivir) 100 mg vials, a critical COVID-19 treatment medication. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical....